Hosted on MSN1mon
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial showsLynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe ... at the Dana-Farber Cancer Institute in Boston, said in the news release. Dr. Douglas Marks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback